---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-084844"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:20:12.640114+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aldeyra resubmits reproxalap NDA for dry eye disease after positive Phase 3 trial

## Summary
- Resubmission includes positive results from FDA-requested symptom trial.
- Phase 3 dry eye chamber trial met primary endpoint (ocular discomfort, P=0.004).
- If approved, reproxalap would be first chronic dry eye therapy with acute symptom and redness data.
- FDA review expected within 6 months of acceptance; acknowledgment in 30 days.
- Reproxalap showed acute activity in reducing dry eye symptoms and ocular redness in trials.

## SEC filing metadata
- accession: 0001213900-24-084844
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/0001213900-24-084844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/ea021662501-8k_aldeyra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-084844
- JSON: https://secwatch.observer/filing/0001213900-24-084844.json
- Plain text: https://secwatch.observer/filing/0001213900-24-084844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.